# Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19

> **NCT04477993** · PHASE2,PHASE3 · TERMINATED · sponsor: **Vanderson Geraldo Rocha** · enrollment: 5 (actual)

## Conditions studied

- Severe Acute Respiratory Syndrome Coronavirus 2
- SARS-CoV2

## Interventions

- **DRUG:** Janus Kinase Inhibitor (ruxolitinib)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04477993
- **Lead sponsor:** Vanderson Geraldo Rocha
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-14
- **Primary completion:** 2021-03-29
- **Final completion:** 2021-03-29
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04477993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04477993, "Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04477993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*